• Alectinib: Capsule 150 mg; Alecensa®
• Bimekizumab: Injection 160 mg in 1 mL single use pre-filled pen, Injection 160 mg in 1 mL single use pre-filled syringe, Injection 320 mg in 2 mL single use pre-filled pen, Injection 320 mg in 2 mL single use pre-filled syringe; Bimzelx®
• Dostarlimab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Jemperli®
• Durvalumab and Tremelimumab: Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi®; Tremelimumab: Solution concentrate for I.V. infusion 300 mg in 15 mL; Imjudo®
• Empagliflozin: Tablet 10 mg; Jardiance®
• Etonogestrel with Ethinylestradiol: Vaginal ring containing etonogestrel 11.7 mg with ethinylestradiol 2.7 mg; NuvaRing®
• Guselkumab: Injection 100 mg in 1 mL single use pre-filled pen; Tremfya®
• Omalizumab: Injection 75 mg in 0.5 mL single dose pre-filled syringe, Injection 150 mg in 1 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled syringe, Injection 75 mg in 0.5 mL single dose pre-filled pen, Injection 150 mg in 1 mL single dose pre-filled pen, Injection 300 mg in 2 mL single dose pre-filled pen; Xolair®
• Pegcetacoplan: Solution for subcutaneous infusion 1,080 mg in 20 mL; Empaveli®
• Pioglitazone: Tablet 15 mg (as hydrochloride), Tablet 30 mg (as hydrochloride), Tablet 45 mg (as hydrochloride); Actos®
• Ranibizumab: Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, Solution for intravitreal injection 2.3 mg in 0.23 mL; Lucentis®
• Repotrectinib: Capsule 40 mg, Capsule 160 mg; Augtyro™
• Ublituximab: Solution concentrate for I.V. infusion 150 mg in 6 mL (25 mg per mL); Briumvi®

The following Public Summary Documents have been updated:

November 2024 PBAC Meeting

• IncobotulinumtoxinA: Lyophilised powder for injection 100 units; Xeomin® - November 2024

March 2025 PBAC Meeting

• Teprotumumab: Powder for I.V. infusion 500 mg; Tepezza® - March 2025